ERBB2 and breast carcinoma: Our gene expression/survival correlation data revealed that high co-expression of HER2, JAM-A and FOXA1 mRNA was associated with poorer survival characteristics (both distant metastasis-free survival and recurrence-free survival) in HER2-positive breast cancer patients.